EGFR and non-small cell lung carcinoma: Therefore, the aim of this study was to evaluate the treatment patterns and outcomes in patients with EGFR-mutated advanced or metastatic NSCLC, diagnosed between 2018 and 2021 and treated in a Portuguese Comprehensive Cancer Center (IPO Porto).